Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Related to this article
Interim phase 2 results show carotuximab plus apalutamide sharply extends progression-free survival in metastatic castration-resistant prostate cancer, prompting earlier-use trial changes.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Addressing Disparities in Stem Cell Transplant for Myeloma
2
Evaluating a Virtual Care Navigation Program for Enhanced Oral Oncolytics Management
3
Trials of Bispecifics in Smoldering Myeloma Look Beyond Delaying Progression
4
Opamtistomig Earns FDA Fast Track in First-Line Biliary Tract Cancer
5